Vitera Healthcare Solutions Receives Frost & Sullivan Award

Tampa, Florida – Sept. 17, 2013 – Vitera Healthcare Solutions, the nation’s premier provider of ambulatory electronic health records (EHR) and practice management software and services, announced today that it has earned the 2013 Customer Value Enhancement Award from Frost & Sullivan for providing outstanding customer value and helping physicians’ practices thrive in a complex, changing healthcare environment.

Frost & Sullivan is a 50-year-old global research organization of 1,800 analysts and consultants who monitor more than 300 industries, including healthcare. The Award for Customer Value Enhancement is presented each year to the company that demonstrates outstanding customer value and focuses on improving the return on the investment for customers.

“This is acknowledgment of Vitera’s transformation,” says Matthew Hawkins, CEO of Vitera Healthcare Services. “Every day the Vitera team works hard to create value for our customers — that’s what we do. We’re especially honored to receive this award as we continue to provide customers innovative, easy-to-use solutions that deliver increased practice efficiency, profitability and improved patient care.”

According to Frost & Sullivan Principal Analyst Nancy Fabozzi, “Vitera Healthcare Solutions improves customer value through myriad new efforts related to product innovation, customer service infrastructure, staffing, and strategic acquisitions and partnerships. Vitera’s strong platform of expertise and its continuing commitment to excellence will enable the company to expand and enhance its presence across a highly dynamic and rapidly shifting healthcare landscape.”

“I can completely understand why Vitera would be recognized with an award focused on delivering customer value,” says Donna Rizzio, CMPE, Practice Administrator for Hartford Orthopedic Surgeons. Rizzio, who speaks regularly with practices around the country, serves on the board of the Connecticut Medical Group Management Association and committees with the American Academy of Orthopaedic Executives. “Vitera is always seeking to improve. I know I have access to anyone at all levels of the organization.”

In its research analysis, Frost & Sullivan analysts reported that they based the award on four key performance drivers for Vitera:

  • Relentless focus on customers’ needs
  • A comprehensive suite of technology solutions that appeal to a variety of needs
  • A strong legacy brand that provides deep understanding of the medical practice market segment
  • Refocused on core mission, building a solid strategic vision for the future

To find out more about Vitera’s commitment to its customers, visit www.viterahealthcare.com.

About Vitera Healthcare Solutions
Vitera Healthcare Solutions provides end-to-end clinical and financial technology solutions so physicians and medical professionals can work with patients instead of paperwork. Serving more than 415,000 healthcare professionals including 85,000 physicians, Vitera Healthcare Solutions provides electronic health records and practice management systems, processes 33 million transactions and 2 million e-prescriptions monthly, and serves several specialties including primary care, OB/GYN, pediatrics, cardiology and orthopedics in all sized practices and Community Health Centers. Physician focused and patient centric, Vitera Healthcare Solutions is based in Tampa, FL. For more information, visit www.viterahealthcare.com or call (877) 932-6301. Follow Vitera Healthcare Solutions on Facebook, http://www.facebook.com/ViteraHealthcare, and Twitter, http://twitter.com/#!/ViteraHealth.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.